Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells

被引：0
|
作者：
Amjad Ali
Hema Unnikannan
Jasmin Shafarin
Khuloud Bajbouj
Jalal Taneera
Jibran Sualeh Muhammad
Haydar Hasan
Albert Salehi
Samir Awadallah
Mawieh Hamad
机构：
[1] University of Sharjah,Sharjah Institute for Medical Research
[2] University of Sharjah,Department of Basic Medical Sciences, College of Medicine
[3] University of Sharjah,Department of Clinical Nutrition and Dietetics, College of Health Sciences
[4] Lund University,Department of Clinical science, UMAS, Clinical Research Center
[5] University of Gothenburg,Department of Neuroscience and Physiology, Metabolic Research Unit
[6] University of Sharjah,Department of Medical Laboratory Sciences, College of Health Sciences
来源：
Endocrine | 2022年 / 76卷
关键词：
Metformin; PCSK9; HNF-1α; SREBP2; LDL-cholesterol; LDLR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：543 / 557
页数：14
相关论文
共 50 条
  • [31] Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Wang, Yu
    Ye, Jiantao
    Li, Jie
    Chen, Cheng
    Huang, Junying
    Liu, Peiqing
    Huang, Heqing
    CARDIOVASCULAR DIABETOLOGY, 2016, 15
  • [32] FoxO3 Transcription Factor and Sirt6 Deacetylase Regulate Low Density Lipoprotein (LDL)-cholesterol Homeostasis via Control of the Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Gene Expression
    Tao, Rongya
    Xiong, Xiwen
    DePinho, Ronald A.
    Deng, Chu-Xia
    Dong, X. Charlie
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (41) : 29252 - 29259
  • [33] A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
    Ni, Yan G.
    Condra, Jon H.
    Orsatti, Laura
    Shen, Xun
    Di Marco, Stefania
    Pandit, Shilpa
    Bottomley, Matthew J.
    Ruggeri, Lionello
    Cummings, Richard T.
    Cubbon, Rose M.
    Santoro, Joseph C.
    Ehrhardt, Anka
    Lewis, Dale
    Fisher, Timothy S.
    Ha, Sookhee
    Njimoluh, Leila
    Wood, Dana D.
    Hammond, Holly A.
    Wisniewski, Douglas
    Volpari, Cinzia
    Noto, Alessia
    Lo Surdo, Paola
    Hubbard, Brian
    Carfi, Andrea
    Sitlani, Ayesha
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (17) : 12882 - 12891
  • [34] Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors
    Leander, Karin
    Malarstig, Anders
    van't Hooft, Ferdinand M.
    Hyde, Craig
    Hellenius, Mai-Lis
    Troutt, Jason S.
    Konrad, Robert J.
    Ohrvik, John
    Hamsten, Anders
    de Faire, Ulf
    CIRCULATION, 2016, 133 (13) : 1230 - 1239
  • [35] Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
    Nozue, Tsuyoshi
    Hattori, Hiroaki
    Ogawa, Kazuyuki
    Kujiraoka, Takeshi
    Iwasaki, Tadao
    Hirano, Tsutomu
    Michishita, Ichiro
    LIPIDS IN HEALTH AND DISEASE, 2016, 15 : 1 - 7
  • [36] New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation
    Hu, Die
    Guo, Yanhong
    Wu, Renrong
    Shao, Tiannan
    Long, Junke
    Yu, Bilian
    Wang, Huilun
    Luo, Yonghong
    Lu, Haocheng
    Zhang, Jifeng
    Chen, Y. Eugene
    Peng, Daoquan
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2021, 41 (04) : e208 - e223
  • [37] Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies
    Brandts, Julia
    Ray, Kausik K.
    CURRENT OPINION IN LIPIDOLOGY, 2020, 31 (04) : 182 - 186
  • [38] Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control
    Bojanin, Dragana
    Vekic, Jelena
    Milenkovic, Tatjana
    Vukovic, Rade
    Zeljkovic, Aleksandra
    Stefanovic, Aleksandra
    Janac, Jelena
    Ivanisevic, Jasmina
    Mitrovic, Katarina
    Miljkovic, Milica
    Spasojevic-Kalimanovska, Vesna
    ATHEROSCLEROSIS, 2019, 280 : 14 - 20
  • [39] Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression
    Wang, Dandan
    Yang, Xiaoxiao
    Chen, Yuanli
    Gong, Ke
    Yu, Maoyun
    Gao, Yongyao
    Wu, Ximei
    Hu, Huaqing
    Liao, Chenzhong
    Han, Jihong
    Duan, Yajun
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2020, 295 (47) : 15870 - 15882
  • [40] Can proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors regress coronary atherosclerotic plaque? A systematic review and meta-analysis
    Wu, Zijia
    Gao, Lulan
    Lin, Zhihai
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2023, 15 (01): : 452 - 465
12345